CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to ...

Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include: Needham analyst Gil ...

Amber Salzman, Ph.D., CEO at Epicrispr Biotechnologies, joined the Business of Biotech live in Boston to talk about ...

A Ph.D. student in biomolecular engineering at the University of California, Santa Cruz, has built a software program ...

CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a substantial price movement, increasing 57% over the last quarter. This significant rise aligns with key developments, such as the company's inclusion in ...

UC Berkeley and Caltech researchers identified a gene circuit in zebrafish that allows heart regeneration after injury. Using ...

The global CRISPR gene editing market size is calculated at USD 4.77 billion in 2025 and is expected to reach around USD ...

CRISPR is revolutionizing medicine by enabling precise DNA edits, treating genetic diseases like sickle cell anemia and ...

Scientists have created a near-copy of the long-extinct dire wolf. Using advanced CRISPR gene editing tech, it now looks ...

Personalized CRISPR cures for children born with rare genetic diseases are now a step closer to being more widely available.

New research has found a novel target with therapeutic potential for metastatic eye melanoma—an aggressive eye cancer—with ...